GlassScriptPhysician profile
Megha Rao
NPI 1629368097
$2,534.75
in general payments reported to CMS, 2019-2025
25 companies · $653 in 2025
The $653 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $41.09 · 2021: $50.91 · 2022: $217 · 2023: $620 · 2024: $787 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $828.33 | 2023-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $242.40 | 2020-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $149.21 | 2025 | Watchman Flx |
| Genzyme Corporation | $145.08 | 2023 | |
| Abiomed | $120.36 | 2024 | Impella |
| Leo Pharma INC. | $120.29 | 2025 | Anzupgo |
| Medtronic, INC. | $119.11 | 2024-2025 | Intellis Adaptivestim, Minimed 780g |
| Edwards Lifesciences Corporation | $111.05 | 2019 | |
| Intuity Medical INC | $87.54 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Lilly USA, LLC | $87.06 | 2019-2025 | Jardiance, Mounjaro |
| Kestra Medical Technology Services, INC. | $69.97 | 2025 | Assure Wcd |
| Exact Sciences Corporation | $57.89 | 2023-2024 | Cologuard Collection Kit |
| Cvrx, INC. | $53.49 | 2025 | Barostim Neo System |
| Pfizer INC. | $51.49 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $48.67 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $47.24 | 2024 | Omnipod |
| Scilex Pharmaceuticals INC. | $41.96 | 2022 | |
| Amryt Pharma Holdings LTD | $37.08 | 2023 | Myalept |
| Xeris Pharmaceuticals, INC. | $30.19 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2023 | Jardiance |
| Corcept Therapeutics | $15.75 | 2022 | |
| Mannkind Corporation | $14.95 | 2019 | |
| Amarin Pharma, INC. | $12.92 | 2021 | |
| Merck Sharp & Dohme LLC | $12.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megha Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.